Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
D000284:Administration, Oral; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage* / Q000627:therapeutic use; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*
D006834:Hydrazines; D004295:Dihydroxyphenylalanine